Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Grifols, S.A. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Grifols, S.A. - Product Pipeline Review - 2015', provides an overview of the Grifols, S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Grifols, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Grifols, S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Grifols, S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Grifols, S.A.'s pipeline products Reason To Buy - Evaluate Grifols, S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Grifols, S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Grifols, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Grifols, S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grifols, S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Grifols, S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Grifols, S.A. Snapshot 5 Grifols, S.A. Overview 5 Key Information 5 Key Facts 5 Grifols, S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Grifols, S.A. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Grifols, S.A. - Pipeline Products Glance 13 Grifols, S.A. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Grifols, S.A. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Phase 0 Products/Combination Treatment Modalities 16 Grifols, S.A. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Grifols, S.A. - Unknown Stage Pipeline Products 18 Unknown Products/Combination Treatment Modalities 18 Grifols, S.A. - Drug Profiles 19 albumin (human) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ARD-3150 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 immune globulin (human) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Recombinant A1PI 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Human Plasmin 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 fibrinogen concentrate (human) 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ARD-3100 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Human Coagulation Factor-VIII (Recombinant) 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Recombinant Plasmin 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Grifols, S.A. - Pipeline Analysis 33 Grifols, S.A. - Pipeline Products by Target 33 Grifols, S.A. - Pipeline Products by Route of Administration 34 Grifols, S.A. - Pipeline Products by Molecule Type 35 Grifols, S.A. - Pipeline Products by Mechanism of Action 36 Grifols, S.A. - Recent Pipeline Updates 37 Grifols, S.A. - Dormant Projects 43 Grifols, S.A. - Locations And Subsidiaries 44 Head Office 44 Other Locations & Subsidiaries 44 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Grifols, S.A., Key Information 5 Grifols, S.A., Key Facts 5 Grifols, S.A. - Pipeline by Indication, 2015 8 Grifols, S.A. - Pipeline by Stage of Development, 2015 9 Grifols, S.A. - Monotherapy Products in Pipeline, 2015 10 Grifols, S.A. - Partnered Products in Pipeline, 2015 11 Grifols, S.A. - Partnered Products/ Combination Treatment Modalities, 2015 12 Grifols, S.A. - Phase III, 2015 13 Grifols, S.A. - Phase II, 2015 14 Grifols, S.A. - Phase I, 2015 15 Grifols, S.A. - Phase 0, 2015 16 Grifols, S.A. - Preclinical, 2015 17 Grifols, S.A. - Unknown, 2015 18 Grifols, S.A. - Pipeline by Target, 2015 33 Grifols, S.A. - Pipeline by Route of Administration, 2015 34 Grifols, S.A. - Pipeline by Molecule Type, 2015 35 Grifols, S.A. - Pipeline Products by Mechanism of Action, 2015 36 Grifols, S.A. - Recent Pipeline Updates, 2015 37 Grifols, S.A. - Dormant Developmental Projects,2015 43 Grifols, S.A., Other Locations 44 Grifols, S.A., Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.